- Ed treatment MAXON ACTIVE is a medicine containing the composition of sildenafil (sildenafil citrate) - a substance used in the treatment of erectile dysfunction in men. Maxon Active is the drug on market with sildenafil (25 mg dose) available without a prescription!
Composition MAXON ACTIVE:
Each film-coated tablet contains 25 mg of sildenafil sildenafil citrate. Each film-coated tablet strengths of 25 mg contains 1.63 mg lactose monohydrate.
Other ingredients: microcrystalline cellulose, hydroxypropyl cellulose, Croscarmellose sodium, Magnesium stearate, silica colloidal anhydrous, Hypromellose 6cP, L, Titanium dioxide (E171), Macrogol 4000, sodium citrate dihydrate .
Action: MAXON ACTIVE medication OTC (non-prescription), containing the composition of Sildenafil citrate - a substance made famous thanks to "a small blue pills", previously available only on prescription from a doctor's prescription. One pack Maxon Active two tablets each containing 25 mg of sildenafil. This drug is indicated for the treatment of erectile dysfunction in adult men. These disorders are characterized by the inability to achieve or maintain an erection of the penis required to satisfactorily complete sexual intercourse.
Use: The drug Maxon Active is indicated for use in adult men with erectile dysfunction. In order to ensure effective drug Maxon Active sexual stimulation is required.
Note: For your safety, each drug package is accompanied by a diagnostic tool, which will determine whether you can take preparation Maxon Active. Contraindications: - Hypersensitivity to the active substance or to any of the excipients. - Concomitant use of sildenafil with drugs nitric oxide donors (such as amyl nitrite) or nitrates in any form. - the use of PDE5 inhibitors, including sildenafil, and drugs that stimulate guanylate cyclase, such as riocyguat is contraindicated, since it can lead to symptomatic hypotension . - Do not use in men with severe diseases of the cardiovascular system, such as unstable angina or severe heart failure - Contraindicated in patients who have loss of vision in one eye as a result of non arteritis anterior ischemic optic neuropathy (ang.Non-arteritic anterior ischemic optic neuropathy, NAION), regardless of whether it was connected or had no relation with previous PDE5 inhibitor exposure.